Previous studies have shown that in triple-negative breast cancer, paclitaxel can promote stem cell phenotype by inducing the secretion of IL-8 while inhibiting the activation of NF-κB can reduce the production of cancer stem cells (CSCs).10 Here, NFKB1 is linked to triple-negative breast carcinoma.